Literature DB >> 2468608

Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination.

R E Mandrell1, W D Zollinger.   

Abstract

Antibody levels in 41 sets of human acute- and convalescent-phase meningococcal sera were compared with those in 23 sets of human prevaccination and 2-week postvaccination sera. We used a modification of a solid-phase radioimmunoassay (SPRIA) technique to test each of the human serum samples as inhibitors of monoclonal antibodies (MAbs) that bind (HIMSPRIA) to the outer membrane complex from a 2a:P1.2:P5.1 strain. We used three murine MAbs specific for the 2a, P1.2, and P5.1 epitopes on meningococcal class 1, 2, and 5 proteins, respectively, to detect antibodies with similar specificities in human sera. Each of 40 available matching strains from patients were also screened with the three MAbs in a nitrocellulose spot blot assay. A total of 37 (92%) were positive for the 2a epitope, 36 (90%) were positive for the P1.2 epitope, and 16 (40%) were positive for the P5.1 epitope. Of 38 available convalescent-phase sera, 27 (71%) matched with these strains and had detectable inhibiting antibody for each of the MAb-defined protein epitopes of the infecting strain. Three convalescent-phase sera had no HIMSPRIA activity for MAb-defined epitopes that were present on the infecting strain; others had activity for one or two of the epitopes. The results were similar for pre- and postvaccination sera. The average level of HIMSPRIA activity for the P1.2 epitope was greater than fivefold higher in postvaccination sera compared with that in convalescent-phase sera. Sera with distinct patterns of HIMSPRIA activity also were tested by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot analysis and showed a correlation between the HIMSPRIA activity for particular epitopes and the level of antibody binding to the immunoblotted proteins possessing those epitopes. A comparison of the HIMSPRIA and the bactericidal activity of selected postvaccination sera indicated a possible correlation between HIMSPRIA and bactericidal activity, but it also suggested the presence of bactericidal antibodies with specificities other than those defined by the MAbs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2468608      PMCID: PMC313318          DOI: 10.1128/iai.57.5.1590-1598.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

Review 1.  Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes.

Authors:  C E Frasch; W D Zollinger; J T Poolman
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

2.  Influence of nutrient limitation and low pH on serogroup B Neisseria meningitidis capsular polysaccharide levels: correlation with virulence for mice.

Authors:  L Masson; B E Holbein
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

3.  Analyses of gonococcal lipopolysaccharide in whole-cell lysates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis: stable association of lipopolysaccharide with the major outer membrane protein (protein I) of Neisseria gonorrhoeae.

Authors:  P J Hitchcock
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

4.  Monoclonal antibodies to serotype 2 and serotype 15 outer membrane proteins of Neisseria meningitidis and their use in serotyping.

Authors:  W D Zollinger; E E Moran; H Connelly; R E Mandrell; B Brandt
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

5.  Filter radioimmunoassay, a method for large-scale serotyping of Neisseria meningitidis.

Authors:  S de Marie; J H Hoeijmakers; J T Poolman; H C Zanen
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

6.  Inhibition of serum bactericidal reaction by lipopolysaccharide.

Authors:  M Sansano; A M Reynard; R K Cunningham
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

7.  Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model.

Authors:  L Y Wang; C E Frasch
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

8.  Elaboration of a 3.6-kilodalton lipooligosaccharide, antibody against which is absent from human sera, is associated with serum resistance of Neisseria gonorrhoeae.

Authors:  H Schneider; J M Griffiss; R E Mandrell; G A Jarvis
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

9.  Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide.

Authors:  C Moreno; M R Lifely; J Esdaile
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

10.  Neisserial antigen H.8 is immunogenic in patients with disseminated gonococcal and meningococcal infections.

Authors:  J R Black; W J Black; J G Cannon
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

View more
  30 in total

1.  Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.

Authors:  Kay O Johswich; Shannon E McCaw; Lea Strobel; Matthias Frosch; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

4.  Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.

Authors:  L G Milagres; M C Gorla; C T Sacchi; M M Rodrigues
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

5.  Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains.

Authors:  B Rokbi; M Mignon; G Maitre-Wilmotte; L Lissolo; B Danve; D A Caugant; M J Quentin-Millet
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

6.  Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity.

Authors:  J Newcombe; L-J Eales-Reynolds; L Wootton; A R Gorringe; S G P Funnell; S C Taylor; J J McFadden
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

8.  Neisserial porins inhibit human neutrophil actin polymerization, degranulation, opsonin receptor expression, and phagocytosis but prime the neutrophils to increase their oxidative burst.

Authors:  R Bjerknes; H K Guttormsen; C O Solberg; L M Wetzler
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

9.  Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease.

Authors:  H K Guttormsen; L M Wetzler; A Naess
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

Review 10.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.